Suspension of trading
Valuation Arcellx, Inc.
Stocks
ACLX
US03940C1009
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-04-27 EDT
|
5-day change | 1st Jan Change | ||
| 115.07 USD | +0.03% |
|
-.--% | +76.49% |
| 05-07 | Gilead Sciences Expects Loss This Year on Acquired R&D Expenses | DJ |
| 05-07 | Gilead raises 2026 sales forecast, flags profit hit from acquisitions | RE |
Company Valuation: Arcellx, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 1,359 | 2,882 | 4,147 | 3,770 |
| Change | - | 112.13% | 43.89% | -9.09% |
| Enterprise Value (EV) 1 | 1,192 | 2,250 | 3,575 | 3,302 |
| Change | - | 88.82% | 58.87% | -7.65% |
| P/E | -5.97x | -37.7x | -38.3x | -16x |
| PBR | 6.67x | 5.98x | 9.16x | 9.39x |
| PEG | 0.1x | 0.5x | -1.1x | -0x |
| Capitalization / Revenue | - | 26,124,643x | 38,420,790x | 169,166,795x |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -6.28x | -25.6x | -27x | -13.4x |
| EV / EBIT | -6.23x | -25x | -26x | -13x |
| EV / FCF | -12.2x | 184x | 238x | -34x |
| FCF Yield | -8.22% | 0.54% | 0.42% | -2.94% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -5.19 | -1.471 | -2.004 | -4.066 |
| Distribution rate | - | - | - | - |
| Net sales | - | 110.3 | 107.9 | 22.29 |
| EBITDA 1 | -189.9 | -87.84 | -132.4 | -246.4 |
| EBIT 1 | -191.3 | -89.88 | -137.6 | -253.1 |
| Net income 1 | -188.7 | -70.69 | -107.3 | -228.9 |
| Net Debt 1 | -166.7 | -631.6 | -571.6 | -468.1 |
| Reference price 2 | 30.98 | 55.50 | 76.69 | 65.20 |
| Nbr of stocks (in thousands) | 43,854 | 51,929 | 54,075 | 57,823 |
| Announcement Date | 3/29/23 | 2/28/24 | 2/27/25 | 2/26/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.75B | |
| 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 32.07x | 35.07x | 13.80x | 0.31% | 29.33B | |
| Weighted average by Cap. | 27.26x | 47.36x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ACLX Stock
- Valuation Arcellx, Inc.
Select your edition
All financial news and data tailored to specific country editions
